A transductionally retargeted adenoviral vector for virotherapy of her2/neu-expressing prostate cancer

Human Gene Therapy

Volumn 23, Issue 1, 2012, Pages 70-82

  Magnusson, M K ^a   Kraaij, R ^b   Leadley, R M ^c   De Ridder, C M A ^b   Van Weerden, W M ^b   Van Schie, K A J ^b   Van Der Kroeg, M ^b   Hoeben, R C ^d   Maitland, N J ^c   Lindholm, L ^e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^c UNIVERSITY OF YORK   (United Kingdom)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e 429 30 Kullavik ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOLYTIC ADENOVIRUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA MODIFICATION; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MOTIF; SUBSTITUTION REACTION; SURVIVAL TIME; VIRION;

ADENOVIRIDAE; ANIMALS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NECROSIS; ONCOLYTIC VIROTHERAPY; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; COXSACKIEVIRUS; MUS MUSCULUS;

EID: 84855868756     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2011.016     Document Type: Article

References (63)

1. Auclerc, G., Antoine, E.C., Cajfinger, F., et al. (2000). Management of advanced prostate cancer. Oncologist 5, 36-44. (Pubitemid 30127543)
2. Barry, M.A., Hofherr, S.E., Chen, C.Y., et al. (2009). Systemic delivery of therapeutic viruses. Curr. Opin. Mol. Ther. 11, 411-420.
3. Bayo-Puxan, N., Cascallo, M., Gros, A., et al. (2006). Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob-mediated retargeting. J. Gen. Virol. 87, 2487-2495.
4. Bayo-Puxan, N., Gimenez-Alejandre, M., Lavilla-AlonSO, S., et al. (2009). Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum. Gene Ther. 20, 1214-1221.
5. Bergelson, J.M., Cunningham, J.A., Droguett, G., et al. (1997). Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323. (Pubitemid 27114163)
6. Bernhard, H., Neudorfer, J., Gebhard, K., et al. (2008). Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol. Immunother. 57, 271-280. (Pubitemid 350159915)
7. Cardin, A.D., and Weintraub, H.J. (1989). Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9, 21-32. (Pubitemid 19046087)
8. Cheng, W.S., Dzojic, H., Nilsson, B., et al. (2006). An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer. Cancer Gene Ther. 13, 13-20. (Pubitemid 41816345)
9. Dechecchi, M.C., Tamanini, A., Bonizzato, A., and Cabrini, G. (2000). Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology 268, 382-390. (Pubitemid 30159987)
10. De Vrij, J., Willemsen, R.A., Lindholm, L., et al. (2010). Adeno-virus-derived vectors for prostate cancer gene therapy. Hum. Gene Ther. 21, 795-805.
11. Di Paolo, N.C., Kalyuzhniy, O., and Shayakhmetov, D.M. (2007). Fiber shaft-chimeric adenovirus vectors lacking the KKTK-motif efficiently infect liver cells in vivo. J. Virol. 81, 12249-2259. (Pubitemid 350085840)
12. Elsasser-Beile, U., Buhler, P., and Wolf, P. (2009). Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr. Drug Targets 10, 118-125.
13. El Sheikh, S.S., Domin, J., Abel, P., et al. (2004). Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 6, 846-853. (Pubitemid 40041504)
14. Fisher, K.D., Stallwood, Y., Green, N.K., et al. (2001). Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8, 341-348. (Pubitemid 32241933)
15. Freytag, S.O., Stricker, H., Pegg, J., et al. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate-to high-risk prostate cancer. Cancer Res. 63, 7497-7506. (Pubitemid 37413494)
16. Henning, P., Magnusson, M.K., Gunneriusson, E., et al. (2002). Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum. Gene Ther. 13, 1427-1439.
17. Henning, P., Andersson, K.M., Frykholm, K., et al. (2005). Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther. 12, 211-224. (Pubitemid 40220623)
18. Hileman, R.E., Fromm, J.R., Weiler, J.M., and Linhardt, R.J. (1998). Glycosaminoglycan-protein interactions: Definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20, 156-167. (Pubitemid 28132111)
19. Hudis, C.A. (2007). Trastuzumab: Mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51. (Pubitemid 47026733)
20. Kelly, E., and Russell, S.J. (2007). History of oncolytic viruses: Genesis to genetic engineering. Mol. Ther. 15, 651-659. (Pubitemid 46431984)
21. Kraaij, R., van Weerden, W.M., De Ridder, C.M., et al. (2002). Validation of transrectal ultrasonographic volumetry for or-thotopic prostate tumours in mice. Lab. Anim. 36, 165-172. (Pubitemid 34311410)
22. Kreppel, F., Gackowski, J., Schmidt, E., and Kochanek, S. (2005). Combined genetic and chemical capsid modifications enable flexible and efficient de-and retargeting of adenovirus vectors. Mol. Ther. 12, 107-117. (Pubitemid 40862362)
23. Kuppen, P.J., Van der Eb, M.M., Jonges, L.E., et al. (2001). Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer. Histochem. Cell Biol. 115, 67-72. (Pubitemid 32202055)
24. Kuster, K., Koschel, A., Rohwer, N., et al. (2010). Down-regulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1a. Cancer Gene Ther. 17, 141-146.
25. Lang, S.H., Smith J., Hyde, C., et al. (2006). Differentiation of prostate epithelial cell cultures by Matrigel/stromal cell glandular reconstruction. In Vitro Cell Dev. Biol. Anim. 42, 273-280. (Pubitemid 44851885)
26. Li, Z.Y., Ni, S., Yang, X., et al. (2004). Xenograft models for liver metastasis: Relationship between tumor morphology and ad-enovirus vector transduction. Mol. Ther. 9, 650-657. (Pubitemid 38660417)
27. Limpens, J., Schroder, F.H., De Ridder, C.M., et al. (2006). Combined lycopene and vitamin E treatment suppresses the growth of PC-346C human prostate cancer cells in nude mice. J. Nutr. 136, 1287-1293.
28. Magnusson, M.K., Hong, S.S., Boulanger, P., and Lindholm, L. (2001). Genetic retargeting of adenovirus: Novel strategy employing " deknobbing" of the fiber. J. Virol. 75, 7280-7289. (Pubitemid 32737986)
29. Magnusson, M.K., Henning, P., Myhre, S., et al. (2007). Adeno-virus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu. Cancer Gene Ther. 14, 468-479. (Pubitemid 46588191)
30. Maitland, N., Chambers, K., Georgopoulos, L., et al. (2010). Gene transfer vectors targeted to human prostate cancer: Do we need better preclinical testing systems? Hum. Gene Ther. 21, 815-827.
31. Maitland, N.J., Macintosh, C.A., Schmitz, C., and Lang, S.H. (2004). Immortalization of human prostate cells with the human papillomavirus type 16 E6 gene. Methods Mol. Med 88, 275-285.
32. Marques, R.B., Dits, N.F., Erkens-Schulze, S., et al. (2010). Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PloS One 5, e13500.
33. Millson, A., Suli, A., Hartung, L., et al. (2003). Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J. Mol. Diagn. 5, 184-190. (Pubitemid 36974730)
34. Morgan, R.A., Yang, J.C., Kitano, M., et al. (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851.
35. Morris, M.J., Reuter, V.E., Kelly, W.K., et al. (2002). HER-2 profiling and targeting in prostate carcinoma. Cancer 94, 980-986.
36. Myhre, S., Henning, P., Friedman, M., et al. (2009). Re-targeted adenovirus vectors with dual specificity: Binding specificities conferred by two different Affibody molecules in the fiber. Gene Ther. 16, 252-261.
37. Nahta, R., and Esteva, F.J. (2003). HER-2-targeted therapy: Lessons learned and future directions. Clin. Cancer Res. 9, 5078-5084. (Pubitemid 37413555)
38. Neto, A.S., Tobias-Machado, M., Wroclawski, M.L., et al. (2010). Her-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis. J. Urol. 184, 842-850.
39. Nilsson, B., Moks, T., Jansson, B., et al. (1987). A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng. 1, 107-113.
40. Nord, K., Gunneriusson, E., Ringdahl, J., et al. (1997). Binding proteins selected from combinatorial libraries of an a-helical bacterial receptor domain. Nat. Biotechnol. 15, 772-777. (Pubitemid 27329481)
41. Nordberg, E., Orlova, A., Friedman, M., et al. (2008). In vivo and in vitro uptake of 111In, delivered with the Affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. Oncol. Rep. 19, 853-857.
42. Orlova, A., Rosik, D., Sandstrom, M., et al. (2007). Evaluation of [111/114mIn]CHX-A¢¢-DTPA-ZHER2:342, an Affibody ligand conjugate for targeting of HER2-expressing malignant tumors. Q. J. Nucl. Med. Mol. Imaging.
43. Pandha, H.S., Stockwin, L.H., Eaton, J., et al. (2003). Coxsackie B and adenovirus receptor, integrin and major histocompatibil-ity complex class I expression in human prostate cancer cell lines: Implications for gene therapy strategies. Prostate Cancer Prostatic Dis. 6, 6-11. (Pubitemid 36432614)
44. Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659-1672. (Pubitemid 41464705)
45. Press, M.F., Cordon-Cardo, C., and Slamon, D.J. (1990). Expression of Her2-/Neu proto-oncogene in normal human adult and fetal tissues. Oncogene 7, 953-962.
46. Rauen, K.A., Sudilovsky, D., Le, J.L., et al. (2002). Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy. Cancer Res. 62, 3812-3818. (Pubitemid 34728866)
47. Reid, A.H., Attard, G., Danila, D.C., et al. (2010). Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489-1495.
48. Rembrink, K., Romijn, J.C., Van der Kwast, T.H., et al. (1997). Orthotopic implantation of human prostate cancer cell lines: A clinically relevant animal model for metastatic prostate cancer. Prostate 31, 168-174. (Pubitemid 27225200)
49. Schenk, E., Essand, M., Bangma, C.H., et al. (2010). Clinical ad-enoviral gene therapy for prostate cancer. Hum. Gene Ther. 21, 807-813.
50. Signoretti, S., Montironi, R., Manola, J., et al. (2000). Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 92, 1918-1925. (Pubitemid 32036922)
51. Simon, R., Nocito, A., Hubscher, T., et al. (2001). Patterns of her-2/neu amplification and overexpression in primary and met-astatic breast cancer. J. Natl. Cancer Inst. 93, 1141-1146. (Pubitemid 32780965)
52. Slamon, D.J., Godolphin, W., Jones, L.A., et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712. (Pubitemid 19147683)
53. Small, E.J., Bok, R., Reese, D.M., et al. (2001). Docetaxel, estra-mustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin. Oncol. 28, 71-76. (Pubitemid 32947556)
54. Smith, T.A., Idamakanti, N., Marshall-Neff, J., et al. (2003a). Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. Hum. Gene Ther. 14, 1595-1604. (Pubitemid 37452870)
55. Smith, T.A., Idamakanti, N., Rollence, M.L., et al. (2003b). Ade-novirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum. Gene Ther. 14, 777-787. (Pubitemid 36623514)
56. Swift, S.L., Burns, J.E., and Maitland, N.J. (2010). Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res. 70, 347-356.
57. Tannock, I.F., De Wit, R., Berry, W.R., et al. (2004). Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502-1512. (Pubitemid 39315317)
58. Van der Heul-Nieuwenhuijsen, L., Dits, N.F., and Jenster, G. (2009). Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 103, 1574-1580.
59. Van Weerden, W.M., De Ridder, C.M., Verdaasdonk, C.L., et al. (1996). Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am. J. Pathol. 149, 1055-1062. (Pubitemid 26334187)
60. Vives, R.R., Lortat-Jacob, H., and Fender, P. (2006). Heparan sulphate proteoglycans and viral vectors: Ally or foe? Curr. Gene Ther. 6, 35-44.
61. Wickham, T.J., Mathias, P., Cheresh, D.A., and Nemerow, G.R. (1993). Integrins avb3 and avb5 promote adenovirus internali-zation but not virus attachment. Cell 73, 309-319. (Pubitemid 23123309)
62. Wikman, M., Steffen, A.C., Gunneriusson, E., et al. (2004). Selection and characterization of HER2/neu-binding affibody ligands. Protein Eng. Des. Sel. 18, 18.
63. Wortmann, A., Vohringer, S., Engler, T., et al. (2008). Fully de-targeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16, 154-162.